Clinical Trial Update: Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of senaparib and bevacizumab as first-line maintenance therapy for newly diagnosed advanced ovarian cancer tha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Senaparib (senaparib)

Snippet

Sponsor: Fudan University | Conditions: Advanced Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING